Markets:

Overview

News

Currencies

International

Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

12.96 -1.19 (-8.41%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗

September 29, 2026

Via Chartmill

Most active stocks in Tuesday's session ↗

September 29, 2026

Via Chartmill

These stocks are moving in today's session ↗

September 29, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

September 29, 2026

Via Chartmill

Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump ↗

August 06, 2026

Via Chartmill

IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen ↗

June 29, 2026

Via Chartmill

Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market ↗

May 07, 2026

Via Chartmill

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗

February 24, 2026

Via Chartmill

Why Iovance Biotherapeutics Stock Was on Fire Today ↗

September 24, 2026

An influential investment bank resumed its coverage of the company.

Via The Motley Fool

Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains ↗

September 19, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter...

Via MarketBeat

Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.

Via The Motley Fool

Topics Earnings

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗

August 10, 2026

The healthcare stock is now up more than 130% this year.

Via The Motley Fool

Iovance Biotherapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded...

Via MarketBeat

Topics Earnings

Top stock movements in today's session. ↗

August 06, 2026

Via Chartmill

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results ↗

August 06, 2026

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should...

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 06, 2026

Via Chartmill

This Stock Is Up 74% This Year: Is It Too Late to Buy? ↗

July 08, 2026

The biotech is clearly innovative, but sometimes that's not enough.

Via The Motley Fool

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 04, 2026

Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.

Via The Motley Fool

Topics Artificial Intelligence

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 23, 2026

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.

Via The Motley Fool

Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗

June 02, 2026

Tread carefully, but certain factors make this speculative biotech play stand out.

Via The Motley Fool

Iovance (IOVA) Q1 2026 Earnings Transcript ↗

May 08, 2026

Iovance (IOVA) Q1 2026 Earnings Transcript

Via The Motley Fool

This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street ↗

May 02, 2026

It could just as well drop by 50% -- or more -- over the next 12 months.

Via The Motley Fool

Topics Death

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? ↗

April 10, 2026

This oncology specialist has proven innovative abilities.

Via The Motley Fool

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗

March 12, 2026

Via MarketBeat

Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗

March 05, 2026

If you decide to invest in this company, it's probably best to start small.

Via The Motley Fool

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗

March 05, 2026

Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.

Via Stocktwits

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗

February 25, 2026

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Via Stocktwits

Topics Earnings

Curious about the most active stocks on Tuesday? ↗

February 24, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

February 24, 2026

Via Chartmill

Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Iovance (IOVA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.